GlassScriptPhysician profile
Leena A Matthews
NPI 1275796047
$3,522.79
in general payments reported to CMS, 2019-2025
26 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,974 · 2020: $163 · 2021: $17.38 · 2022: $12.33 · 2024: $252 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,431.69 | 2019 | |
| Lilly USA, LLC | $346.41 | 2019-2024 | Mounjaro, Zepbound |
| Valeritas, INC. | $265.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $188.34 | 2019 | |
| Novo Nordisk INC | $179.03 | 2019-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $165.81 | 2019-2020 | |
| Dexcom, INC. | $91.14 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $77.06 | 2019-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.56 | 2019-2024 | Jardiance |
| Amgen INC. | $76.38 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $70.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $70.81 | 2019-2024 | Jynarque |
| Corcept Therapeutics | $59.34 | 2019 | |
| Shire North American Group INC | $56.38 | 2019 | |
| Insulet Corporation | $50.45 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.06 | 2019 | |
| Amarin Pharma, INC. | $46.86 | 2019-2020 | |
| Zealand Pharma US, INC. | $34.60 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $33.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.52 | 2024 | |
| Ibsa Pharma INC. | $27.80 | 2019 | |
| Medtronic, INC. | $23.07 | 2024 | Minimed 780g |
| Ardelyx, INC. | $20.94 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $19.78 | 2019 | |
| Abbott Laboratories | $16.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leena Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.